Introduction {#s1}
============

The centrosome is a membrane-less organelle whose major role is to organize, orient, and regulate the site of microtubule formation. In somatic dividing cells, the centrosome is critical for ensuring faithful and timely chromosome segregation and establishment of the correct cell division axis, whereas in non-dividing and differentiated cells, it is critical for cellular polarization and cilia formation ([@bib16]; [@bib95]). Centrosomes are essential for normal human development and health ([@bib71]). Loss of function mutations in centrosomal proteins, including components of the centriolar cartwheel, elongation machinery, appendages, and pericentriolar material, are responsible for developmental defects such as primary recessive microcephaly ([@bib5]), primordial dwarfism ([@bib8]; [@bib78]; [@bib99]), and ciliopathies ([@bib79]). Defects in centrosome number and structure are a major hallmark of tumorigenesis ([@bib34]; [@bib18]; [@bib71]). Recently, studies in mouse models indicated that centrosome over-duplication concomitant with mutations in *p53* drives tumor formation in the epidermis ([@bib83]) and can drive tumor formation in certain other tissues, even in the absence of concurrent *p53^-/-^* mutations ([@bib60]). Therefore, it is essential to characterize the critical set of proteins required for centrosome assembly to understand the molecular mechanism of disease and identify therapeutic targets ([@bib71]).

Due to its important role in cell and tissue homeostasis, the centrosome is built in a highly-regulated, stepwise manner through the assembly of a multiplicity of protein complexes ([@bib16]; [@bib66]). Significant progress has been made in understanding how centrosome duplication begins in most somatic cells---at the G1/S phase boundary---with the assembly of the cartwheel, a nine-fold symmetrical scaffold made of SAS6, STIL, and CEP135. While SAS6 molecules can undergo remarkable self-assembly in vitro, the kinase Plk4 promotes cartwheel formation and centriole duplication by phosphorylating STIL to favor its interaction with SAS6 ([@bib96]; [@bib62]; [@bib23]; [@bib2]). The initial binding of Plk4 to the centriole is governed by CEP63 ([@bib7]), CEP152 ([@bib7]; [@bib55]; [@bib86]; [@bib22]; [@bib43]; [@bib14]), and CEP192 ([@bib55]; [@bib86]). After cartwheel formation, CPAP, recruited by STIL ([@bib92]), aids in the formation of the centriole microtubule wall ([@bib75]; [@bib82]) by regulating centriolar microtubule plus-end dynamics ([@bib6]; [@bib98]). CEP135 facilitates the stabilization of the centriole structure ([@bib72]; [@bib6]) but may also play a more direct role in initial cartwheel formation as recombinant *Drosophila* SAS6 and Bld10 (*Drosophila* CEP135 homolog) can self-organize into a nine-fold symmetrical cartwheel structure ([@bib39]).

Once the initial steps of procentriole formation occur, centriole elongation can proceed. However, we have a limited understanding of the essential components required for centriole elongation, which happens between S and G2 phases, and how they are assembled in a stepwise manner. CPAP has been shown to interact with CEP120 ([@bib61]) and SPICE ([@bib15]) in a complex that regulates centriole elongation at the centriolar microtubule wall ([@bib1]; [@bib62]). Centrobin has also been implicated in directly regulating centriolar microtubule elongation ([@bib59]; [@bib100]) and stability by binding to α-Tubulin ([@bib36]) and by regulating CPAP levels ([@bib38]; [@bib37]). Centrobin is further required to recruit CP110, a protein forming a cap-like structure on the distal end of the centriole that suppresses centriole elongation ([@bib82]). Proximal to CP110, several proteins localized to the distal luminal end of centrioles such as POC5 ([@bib3]), POC1B ([@bib94]), and OFD1 ([@bib85]) have been implicated in promoting the elongation of the centriole's distal region. More recently, additional proteins have been identified, namely CEP295 ([@bib10]) and RTTN ([@bib12]), which have been proposed to play a scaffolding role in the elongation process by connecting the centriole wall to the luminal centriolar region. However, it remains unclear if there are components in the lumen of the centriole that stabilize interactions with centriolar wall proteins.

RTTN (rotatin) was originally identified as a protein critical for axial rotation and left-right symmetry specification in mice ([@bib25]). Subsequently, mutations in human RTTN have been shown to cause primary microcephaly and primordial dwarfism ([@bib53]; [@bib35]; [@bib8]). Recent reports have shed light on the cellular function of RTTN. The *Drosophila* RTTN homolog, Ana3, was demonstrated to be a centrosomal component critical for maintaining the structural integrity of centrioles ([@bib89]), whereas human RTTN, localized near the centriolar cartwheel, has been shown to be dispensable for initial centriole assembly, but critical for formation of a full-length centriole ([@bib12]). It remains unclear what factors are downstream of RTTN and how they promote the elongation and stabilization of the centriole once the cartwheel is formed.

Here, we characterize human PPP1R35, the product of the gene *C7orf47*, which was previously identified in fractions co-purifying with centrosomes in a high-throughput mass spectrometry study ([@bib50]). Our study demonstrates that PPP1R35 is a centrosomal component located in the proximal centriolar lumen above the cartwheel. We further demonstrate that PPP1R35 is not important for early centriole assembly but is critical for centriole elongation by impacting the recruitment of the microtubule-binding elongation machinery. In addition, we show that PPP1R35 is downstream of RTTN in the elongation pathway and that they form a protein complex. Altogether, we describe a novel centriolar component essential for centriole formation and identify a new mechanistic step downstream of RTTN in the pathway to reach a fully elongated centriole and functional centrosome.

Results {#s2}
=======

PPP1R35 is stably associated with the centrosome {#s2-1}
------------------------------------------------

To examine if PPP1R35 is a bona fide centrosomal protein, we generated a U2OS cell line constitutively expressing GFP-PPP1R35 under the control of a low copy protein expression promoter ([@bib54]), integrated into the genome through the Flp-In system. GFP-PPP1R35 showed two main protein populations: one enriched in a diffraction limited spot located in the middle of the cell adjacent to the nucleus, consistent with centrosomal localization, and a cytoplasmic pool ([Figure 1](#fig1){ref-type="fig"}). To verify that the observed PPP1R35 was located at the centrosomes, we transfected the GFP-PPP1R35 U2OS Flp-In cell line with a vector expressing Centrin 1-mCherry and observed co-localization of Centrin 1-mCherry with GFP-PPP1R35 ([Figure 1a](#fig1){ref-type="fig"}). To examine the dynamics of PPP1R35 during the cell cycle, we conducted long-term live-cell imaging by spinning disc confocal fluorescence microscopy ([Figure 1b](#fig1){ref-type="fig"} and [Video 1](#video1){ref-type="video"}). PPP1R35 was found on two centrosomes (grandmother and mother) throughout the entire cell cycle ([Figure 1b](#fig1){ref-type="fig"}). We observed some cells that have four GFP-PPP1R35 spots prior to mitosis ([Video 1](#video1){ref-type="video"}) and noted that a second GFP-PPP1R35 spot was always present after mitosis, suggesting that PPP1R35 is recruited on daughter centrioles prior to mitosis. To verify that both the mother and daughter centrioles have recruited GFP-PPP1R35, we leveraged the \~1.5 x resolution increase of sub-diffraction live cell imaging. In all G2 cells examined, prior to centrosome separation, two GFP-PPP1R35 spots are resolvable on each of the centrioles (grandmother and mother), confirming that PPP1R35 resides on both the mother and daughter centrioles and must be recruited early in the duplication cycle, in S or early G2 phase ([Figure 1c](#fig1){ref-type="fig"}). To confirm that GFP-PPP1R35 localization is consistent with the endogenous protein, we imaged U2OS cells labeled with antibodies against PPP1R35 and γ-tubulin by confocal microscopy ([Figure 1d](#fig1){ref-type="fig"}) and cells labeled with antibodies against PPP1R35 and CETN1 by 3D structured illumination microscopy (3DSIM), and observed co-localization ([Figure 1e](#fig1){ref-type="fig"}). Since the anti-PPP1R35 antibody showed high background staining we used GFP-PPP1R35 to conduct further studies. To ensure that the GFP tag did not impact the localization of the protein, we examined the morphology of the centrosome by 3DSIM and did not observe a difference between WT and GFP-PPP1R35-expressing U2OS cells ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). Furthermore, we verified that the GFP-PPP1R35 construct did not alter centrosome biogenesis by measuring the total number of CEP152-labeled centrosomes in WT and GFP-PPP1R35-expressing U2OS cells ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}). In addition, the GFP-PPP1R35 construct rescues the centriole duplication phenotype when PPP1R35 levels are knocked down by siRNA targeting the 3' untranslated region (3'UTR, see below Figure 3c).

![PPP1R35 localizes to the centrosome.\
(**a**) Confocal microscopy images of live U2OS cells transfected with GFP-PPP1R35 and Centrin1-mCherry. The insets are magnifications of the boxed centrosomes. Scale bar, 5 µm. (**b**) Still images from time-lapse live-cell spinning-disc confocal microscopy of U2OS cells expressing GFP-PPP1R35. The time elapsed from the start of movie acquisition is printed in each still image. The insets are 5X magnifications of the boxed centrosomes. For clarity, the outlines of mitotic cells are shown. The extra cytosolic green dots observed in the 65 and 108 min panels are due to camera shot-noise. Scale bar, 5 µm. (**c**) Still images from high-speed live-cell imaging of G1/S or early G2 phase centrosome (assignment based on the engaged nature of the centrosomes) on a Leica HyVolution 2 confocal microscope. The time elapsed from the start of the movie is printed in each still image. The mother and daughter centrioles are indicated by m and d, respectively. Scale bar, 250 nm. (**d**) Confocal microscopy images of fixed U2OS cells labeled with an antibody against PPP1R35 and γ-tubulin. For clarity, the cell outline is shown by a white dotted line. The insets are 4X magnifications of the boxed centrosomes. Scale bar, 2 µm. (**e**) 3D Structured Illumination Microscopy images of U2OS cells stained for PPP1R35 and CETN1 (bottom series). For clarity, the cell outline is shown by a white dotted line. The insets are 6X magnifications of the boxed centrosomes. Scale bar, 2 µm. (**f**) Fluorescence recovery after photobleaching (FRAP) experiments of cytosolic (blue circles) and centrosomal (red diamonds) GFP-PPP1R35. Several images were acquired pre-bleach to establish a baseline and then the respective populations were bleached (at \~3 s) and allowed to recover. Results are a mean of 20 cells and error bars depict the standard deviation. (**g**) Table summarizing the parameters extracted from the FRAP experiments.\
10.7554/eLife.37846.006Figure 1---source data 1.Source data for [Figure 1f and g](#fig1){ref-type="fig"} (FRAP experiment).](elife-37846-fig1){#fig1}

###### Live-cell imaging movie of U2OS cells expressing GFP-PPP1R35.

Confocal microscopy movie of live U2OS cells stably expressing GFP-PPP1R35.

10.7554/eLife.37846.007

Next, to determine whether PPP1R35 was continuously recruited or was stably associated to the centrosome, we performed Fluorescence Recovery After Photobleaching (FRAP) experiments. Comparison of the fluorescence recovery curves of the cytoplasmic versus centrosomal PPP1R35 pools revealed that centrosomal PPP1R35 did not fully recover to pre-bleach levels after photobleaching, therefore indicating that the protein has low turnover and is stably associated at the centrosome ([Figure 1f,g](#fig1){ref-type="fig"}). This observation is consistent with a previous analysis that identified PPP1R35 as co-purifying with centrosomal components and observed only a 22% turnover in centrosomal PPP1R35 as measured by stable isotope labeling of amino acids in cell culture (SILAC) mass spectrometry ([@bib50]). Altogether, our imaging experiments demonstrate that PPP1R35 is a resident protein of the centrosome and is recruited to the nascent daughter centriole early in the duplication cycle.

PPP1R35 localizes to the under-characterized proximal centriolar lumen above the cartwheel {#s2-2}
------------------------------------------------------------------------------------------

To further dissect the role of PPP1R35 at the centrosome, we used super-resolution microscopy to precisely map the position of PPP1R35 relative to several reference markers, whose position at the centrosome has been previously characterized by EM and fluorescence imaging ([Figure 2](#fig2){ref-type="fig"}). To perform these experiments, we used linear 3DSIM, a technique that provides a 2-fold resolution increase over standard confocal/widefield fluorescence microscopy, which is sufficient to resolve the relative distribution of many centrosomal proteins and allows for straightforward multicolor imaging ([@bib90]; [@bib65]). 3DSIM imaging showed that GFP-PPP1R35 is located in the centrosomal lumen, as suggested by the position of PPP1R35 in the middle of the ring structure formed by CEP152 ([@bib43]; [@bib14]) ([Figure 2a](#fig2){ref-type="fig"}). Next, we used several proximal (SAS6, CEP135, CPAP, CEP250) and distal (CETN1, POC1B, POC5) proteins to locate the position of PPP1R35 along the centrosomal longitudinal axis. Qualitative assessment of the 3DSIM micrographs showed that the position of PPP1R35 is biased toward proximal markers such as CPAP and CEP135 more than either the utmost proximal (i.e. CEP250) or distal (i.e. CETN1) ends of the centriole ([Figure 2b](#fig2){ref-type="fig"}). To precisely map PPP1R35, we performed a quantitative analysis of the distance between PPP1R35 and many centriolar reference markers. We collected hundreds of 3DSIM images and analyzed micrographs with centriole side views where PPP1R35 was in the same z-plane of the protein of interest for measurement to avoid distortions due to anisotropic resolution ([Figure 2c](#fig2){ref-type="fig"}). 3DSIM molecular mapping shows that PPP1R35 is located furthest from the distal end proteins (Centrin-1: 230 ± 50 nm; POC5: 160 ± 50 nm; POC1B: 140 ± 60 nm), but closer to proximal end markers such as CEP135 (90 ± 40 nm) and CPAP (60 ± 30 nm), yet not as proximal as SAS6 (120 ± 40 nm) or CEP250 (170 ± 50 nm) ([Figure 2d](#fig2){ref-type="fig"}). Together, we conclude that PPP1R35 localizes to the proximal centriolar lumen just above the cartwheel ([Figure 2e](#fig2){ref-type="fig"}).

![PPP1R35 localizes to the proximal end of the centriolar lumen above the cartwheel.\
(**a,b**) 3D structured illumination microscopy (3DSIM) micrographs of U2OS cells expressing GFP-PPP1R35 (treated with digitonin to remove the cytoplasmic PPP1R35 population) and co-stained with CEP152 (**a**) and various other markers (**b**) labeling the distal (POC5, POC1B, CETN1) and proximal (SAS6, CEP135, CPAP, CEP250) regions of the centriole. The cartoon depiction of the centriole is alongside the images to assist in orienting the 3DSIM micrographs. Scale bars, 250 nm. (**c**) By measuring the distances between the fluorescence maxima of PPP1R35 and various centriolar markers on the same z-plane, the distance between GFP-PPP1R35 and the corresponding marker was determined. The fluorescence intensity along the line drawn in the micrograph (green, GFP-PPP1R35; red, POC5; white, CETN1) is plotted as a function of the distance along the line. The grey lines are centered at the fluorescence maxima and the distance between these lines corresponds to the distance between GFP-PPP1R35 and the corresponding marker (POC5 in this example). (**d**) By combining the analysis of the micrographs with these measurements, the position of PPP1R35 was mapped on to the centriole and the distances are shown in a Tukey box and whiskers plot, with the whiskers representing datum within an interquartile range of 1.5 and the band in the box as the mean. (**e**) A cartoon depiction of the localization of PPP1R35 in the centriole relative to the markers depicted in (**b**) and (**d**) with the average distances and standard deviations noted.\
10.7554/eLife.37846.009Figure 2---source data 1.Source data for [Figure 2d and e](#fig2){ref-type="fig"} (PPP1R35 mapping measurements).](elife-37846-fig2){#fig2}

PPP1R35 is critical for centriole component recruitment {#s2-3}
-------------------------------------------------------

Since PPP1R35 is recruited early in the centrosome duplication pathway, we hypothesized that it might play a role in regulating centrosome biogenesis. To test this possibility, we depleted PPP1R35 protein levels in U2OS cells by targeting the mRNA with two non-overlapping siRNA strands, one designed to be complementary to an exon in the conserved C-terminal region and the second to the 3' UTR of the PPP1R35 mRNA ([Figure 3a,b](#fig3){ref-type="fig"}). The specificity of the siRNA strands toward PPP1R35 was validated by western blotting of cells expressing GFP-PPP1R35 ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and RT-qPCR ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). We opted to deplete cells of PPP1R35 via siRNA rather than CRISPR/Cas9 gene editing since previous studies demonstrated cell lethality in the absence of PPP1R35 ([@bib42]; [@bib70]). Cells were treated with siRNA for 72 hr, thereby allowing cells to progress through multiple cell cycles and accumulate any centriolar defects ([Figure 3b](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). With both siRNA strands, a significant decrease was observed in centrosomal staining of CEP152, a protein recruited in the last stages of daughter centriole formation ([@bib32])([Figure 3c](#fig3){ref-type="fig"}). This phenotype is rescued by exogenously expressing GFP-PPP1R35, demonstrating the specificity of the siRNA and the resultant phenotype of PPP1R35 loss ([Figure 3c](#fig3){ref-type="fig"}). We next sought to narrow down the stage of centrosome duplication at which PPP1R35 plays a role by labeling PPP1R35-depleted cells with several centrosomal proteins sequentially recruited during its assembly ([@bib16]; [@bib31]; [@bib63]). This analysis revealed that centriolar components recruited early in the pathway such as SAS6 ([@bib23]), CEP135 ([@bib63]; [@bib31]) and Centrin 1 ([@bib69]), are modestly affected at centrioles in the absence of PPP1R35, as opposed to proteins recruited in later stages, such as CEP295 ([@bib10]), POC1B ([@bib94]), and CEP152 ([@bib63]; [@bib31]) that are drastically reduced ([Figure 3e](#fig3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). To assay for centrosome function, we examined whether centrosomes could recruit the pericentriolar material or efficiently nucleate microtubules in the absence of PPP1R35 by staining for Cdk5rap2 and γ-tubulin. In both cases, we observed a significant reduction upon PPP1R35 knockdown ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}).

![PPP1R35 is critical for centrosome duplication.\
(**a**) Sequence of PPP1R35 with the regions targeted by the siRNA used in this study. (**b**) Schematic representing the timing of the siRNA treatments used in the PPP1R35 knockdown experiments. (**c**) PPP1R35 protein levels were reduced in U2OS cells by treatment with siRNAs targeting either an exon (red bars) or the 3' untranslated region (UTR; orange bars) of the mRNA. The percentage of cells with greater than one CEP152-labeled centrosome, a protein recruited in the later stages of centrosome duplication, is plotted. In this and following figures, the grey bar represents U2OS cells treated with a control scrambled siRNA strand; red bar, U2OS cells treated with a siRNA targeting an exon of PPP1R35; orange bar, U2OS cells treated with a siRNA targeting the 3' UTR of endogenous PPP1R35; the green bar represents U2OS cells treated with the 3'UTR-targeting siRNA with exogenously expressed GFP-PPP1R35. (**d**) Representative micrographs showing decreased numbers of CEP152 positive centrioles in cells treated with PPP1R35 siRNA. Note that CETN1 was not severely perturbed upon treatment with PPP1R35 siRNA. High magnifications of the centrosome for each image are shown in the bottom left corner. Scale bars, 2 µm. (**e**) U2OS cells treated with either an exon (red bars) or the 3'UTR (orange bars) targeting siRNA (grey bars- control siRNA treated) for the different components of the centriole duplication pathway. The corresponding step of centriole duplication to which the different components belong is depicted with arrows below the plot, with the impacted steps highlighted with a red box. (**f**) PPP1R35 protein levels were reduced in U2OS cells by treatment with either of the two PPP1R35-targeting siRNA strands, for time points ranging from 24 to 144 hr and subsequently stained for CEP152. The timeline depicted indicate the timing of the siRNA treatments and subsequent time points when cells were fixed and stained for immunofluorescence. (**g**) 3DSIM micrographs of scrambled- and PPP1R35-siRNA treated cells stained for SAS6 (red) and CEP152 (green). Cells in which two engaged centrosomes were present were analyzed for the presence of a SAS6 cartwheel. Fractions of cells falling into each category are indicated in the top left corner of each micrograph. All scale bars, 250 nm. All error bars show the standard deviation of at least three replicate experiments. Statistics for significance were determined using Barnard's test. All statistical values can be found in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.\
10.7554/eLife.37846.019Figure 3---source data 1.Source data for [Figure 3c and d](#fig3){ref-type="fig"} (blue tabs) (PPP1R35 siRNA phenotype) and 3f (siRNA time-course, labeled with antibodies against CEP152).The blue tabs are also the source data for [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}.](elife-37846-fig3){#fig3}

A more significant impact on centriolar components recruited later in the pathway is more noticeable in a time-course experiment, in which cells are assayed at 24 hr intervals after siRNA treatment ([Figure 3f](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). In these assays, there is little change in the recruitment of early-centriolar components such as SAS6, CETN1, and CEP135 up to the 72 hr time point. In contrast, defective recruitment of other components, such as CPAP and CEP152, is present around the 48 hr time point. When cells treated with PPP1R35 siRNA were stained for CEP152 and SAS6, the proportion of engaged centrosomes with cartwheels was not significantly different ([Figure 3g](#fig3){ref-type="fig"}), further suggesting that PPP1R35 loss does not influence the early stages of centriole biogenesis. It is also noteworthy that at longer timepoints (\>72hr), CETN1 levels drastically decrease suggesting that overall centriole formation is being impacted. Altogether, these results demonstrate that PPP1R35 loss of function results in decreased centrosome number and suggest that PPP1R35 is critical for the recruitment of centriolar components after cartwheel formation.

Biotinylation-dependent proximity mapping of PPP1R35 identifies the microcephaly protein RTTN {#s2-4}
---------------------------------------------------------------------------------------------

To better understand the mechanistic role of PPP1R35 in centriole duplication, we conducted biotinylation-dependent proximity mapping (BioID) ([@bib81]) experiments using stable cell lines expressing protein fusions with a FLAG-BirA (R118G) (henceforth referred to as BirA\*) tag on either the N- or C-terminus of PPP1R35. BioID analysis revealed a proximity map with several high-confidence hits (FDR score \<1%). As expected, the proximity interactome of PPP1R35 shows several centrosomal proteins, including AZI1 (CEP131), CEP85, and KIAA0753 (Moonraker). One of the most robust hits, as evidenced by the high numbers of peptides identified by both N- and C-terminal BirA\* tags, is RTTN, a recently characterized protein (H.-Y. [@bib12]) whose mutations in patients cause microcephaly ([@bib8]; [@bib35]), dwarfism, and polymicrogyria ([@bib53]) ([Figure 4a](#fig4){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Stable HEK293T T-REX Flp-In cell lines showed normal centriolar localization as determined via confocal imaging with the marker CEP152 ([Figure 5f](#fig5){ref-type="fig"}).

![PPP1R35 interacts with the microcephaly protein RTTN, which is required for PPP1R35 recruitment.\
PPP1R35 constructs tagged with a FLAG-tag and mutant R118G Biotin-ligase BirA (BirA\*) on either the N- or C-terminus were used for identification of proteins in proximity to PPP1R35 via BioID (**a**) and directly interacting proteins via FLAG-tag immunoprecipitation (**b**), of which the top hits are shown. The arrow thickness indicates number of peptides identified for each hit and the colour of the circle indicates previously annotated sub-cellular localizations. All hits previously related to centrosomes/cilia are indicated by a red outline. (**c**) Localization of mCherry-RTTN relative to centrin-1 and GFP-PPP1R35 in U2OS cells as determined by 3DSIM. Representative cartoons to assist in orientating the images are shown to the right of the merge micrograph. Scale bar, 250 nm. (**d**) 3DSIM mapping of RTTN (via an anti-RTTN antibody and mCherry-RTTN construct) in relation to PPP1R35, conducted using the same methodology as in [Figure 2c](#fig2){ref-type="fig"} and plotted similarly to [Figure 2d](#fig2){ref-type="fig"}. The values noted are the average distances and standard deviations. (**e**) U2OS cells expressing mCherry-RTTN were treated with 40 pmol of either a control, scrambled siRNA (grey bars), siRNA targeting the PPP1R35 exon (red bars) or 3'UTR of endogenous PPP1R35 (orange bars). (**f**) U2OS cells expressing GFP-PPP1R35 were treated with 40 pmol control siRNA (grey bars) or siRNA targeting RTTN (purple bars) All error bars depict the standard deviation of at least three experimental replicates. Statistics for significance were determined using Barnard's test. All statistical values can be found in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.\
10.7554/eLife.37846.023Figure 4---source data 1.Source data for [Figure 4d](#fig4){ref-type="fig"} (PPP1R35 mapping measurements), 4e (mCherry-RTTN U2OS + PPP1 R35 siRNA), and 4 f (GFP-PPP1R35 U2OS + RTTN siRNA).](elife-37846-fig4){#fig4}

![Conserved serines and putative PP1-binding site are not critical for centriole formation or interaction with RTTN.\
(**a**) PPP1R35 contains a series of conserved serine residues that have been previous shown to be Cdk phosphorylation sites and are conserved in mammalian homologs. Furthermore, mammalian PPP1R35 homologs also possess a canonical PP1-binding site. The corresponding residues in both motifs are indicated on the PPP1R35 cartoon. (**b**) BioID results from N-terminal FLAG-BirA\*-PPP1R35 mutants carrying non-phosphorylatable (S45A, S47A, S52A) or phospho-mimetic (S45D, S47D, S52D) mutations. Please refer to [Figure 4a](#fig4){ref-type="fig"} for map legend. (**c**) To probe the role of the conserved serine residues in centriole duplication, amino acids were mutated to either aspartic acids (to mimic the phosphorylated state) or alanine (to mimic the non-phosphorylated state) of the GFP-PPP1R35 construct and tested to see if they could rescue the reduced CEP152-staining phenotype observed upon treatment of U2OS cells with the 3'UTR siRNA. Similar to the triple alanine mutant, we were unable to generate a S52A mutant, suggesting that this residue may be critical for cell viability. (**d**) BioID results from N-terminal FLAG-BirA\*-PPP1R35 mutants carrying the PP1-binding mutation (V79A, F81A). Please refer to [Figure 4a](#fig4){ref-type="fig"} for map legend. (**e**) To probe the role of the putative PP1-binding site in centriole duplication, the V79 and F81 were mutated to alanine to abolish PP1-binding in the GFP-PPP1R35 construct and tested to see if they could rescue the reduced CEP152-staining phenotype observed upon treatment of U2OS cells with the 3'UTR siRNA. (**f**) Localization of HEK293 Flp-In TREX BirA\*-tagged PPP1R35 cell lines. Confocal microscopy micrographs of HEK293 Flp-In TREX cells expressing BirA\*-tagged WT and mutant PPP1R35 constructs, stained for the FLAG tag (red channel) and CEP152 (green channel). Scale bars, 5 µm. Insets are high magnification of the centrosome. (**g**) Localization of GFP-PPP1R35 mutants in U2OS Flp-In cells. 3DSIM micrographs of U2OS cells expressing various mutant GFP-PPP1R35 constructs (treated with digitonin to remove the cytoplasmic PPP1R35 population) and co-stained with centriolar markers. The cartoon depiction of the centriole is alongside to assist in orienting the 3DSIM micrographs. Scale bars, 200 nm.\
10.7554/eLife.37846.030Figure 5---source data 1.Source data for [Figure 5c and e](#fig5){ref-type="fig"} (mutant GFP-PPP1R35 rescue experiments).](elife-37846-fig5){#fig5}

PPP1R35 forms a complex with RTTN and the two proteins are mutually required for each other's recruitment {#s2-5}
---------------------------------------------------------------------------------------------------------

We reasoned that if PPP1R35 and RTTN are in close proximity to each other and are both located at the centrosome near the cartwheel (H.-Y. [@bib12]), they might form a bona fide protein complex. To test this hypothesis, we performed FLAG immunoprecipitation (IP) of the N- and C-terminal tagged PPP1R35 constructs ([Figure 4b](#fig4){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Notably, RTTN was found to form a complex with the N-terminally tagged BirA\*-PPP1R35. RTTN was the only protein identified with high confidence by BioID that also co-immunoprecipitated with PPP1R35, suggesting a strong link between this microcephaly protein and PPP1R35 function. Interestingly, IP-mass spectrometry data using the N-terminal FLAG-tagged PPP1R35, but not the C-terminal FLAG-tag construct, detected a high-confidence interaction with RTTN. IP with the PPP1R35 C-terminal FLAG-tag construct still identified RTTN peptide counts above that of the controls, but below our confidence level cut-off ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), indicating that the interaction between the two proteins has been severely impaired but not completely abolished. Altogether, this suggests that the binding site might reside within the conserved C-terminal region of PPP1R35.

RTTN is a 298 kDa protein predicted to have an elongated, solenoid conformation ([@bib29]) that has been recently reported to localize to basal bodies ([@bib89]; [@bib53]) and the centrosome (H.-Y. [@bib12]; [@bib89]; [@bib8]). Specifically, RTTN has been shown to localize to the proximal lumen of centrioles near CEP135 and the cartwheel (H.-Y. [@bib12]). To further characterize the structural and functional relationship of PPP1R35 and the microcephaly protein RTTN, we mapped the position of RTTN relative to PPP1R35 by 3DSIM imaging and quantitative analysis ([Figure 4c](#fig4){ref-type="fig"}). To detect RTTN we used both an N-terminal mCherry-RTTN construct and an antibody recognizing residues 50--150 of RTTN. Our data show that RTTN localizes to the proximal centriole and it is located in close proximity to PPP1R35, consistent with our BioID findings (PPP1R35 distance from mCherry-RTTN, 80 ± 50 nm; anti-RTTN, 110 ± 50 nm; [Figure 4d](#fig4){ref-type="fig"}).

To further explore the functional relationship between PPP1R35 and RTTN, we depleted PPP1R35 from U2OS cells by siRNA and examined RTTN recruitment. The presence of RTTN at the centrosome is moderately, yet significantly, diminished upon PPP1R35 depletion ([Figure 4e](#fig4){ref-type="fig"}). When the reciprocal recruitment was explored by RTTN depletion, a major reduction in centrosomal PPP1R35 was observed ([Figure 4f](#fig4){ref-type="fig"}). This phenotype appears to be unrelated to the decrease in centriole number expected as a result of RTTN knockdown ([@bib12]), because the number of cells with at least 2 centrin spots remains unchanged ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), yet the number of cells lacking GFP-PPP1R35 is significantly reduced. These results show that the two proteins co-localize at the centriole and that both proteins are mutually required for each other's recruitment to the centriole, with RTTN exerting a more significant impact on PPP1R35 recruitment to the centriole. Altogether, our data suggest that RTTN and PPP1R35 form a complex and that RTTN acts upstream of PPP1R35.

Conserved serine phosphorylation sites and the canonical PP1-binding site in PPP1R35 are not critical for centrosome duplication {#s2-6}
--------------------------------------------------------------------------------------------------------------------------------

PPP1R35 is a highly conserved protein whose homologs are found across a wide range of eukaryotic species, ranging from the simple multicellular organism *Trichoplax adhaerens* to *Homo sapiens* ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Interestingly, PPP1R35 homologues are found only in *Holozoa* species, correlating well with species presenting centrosomes, with the exception of *Caenorhabditis elegans* ([@bib48]). PPP1R35 can be divided into two major domains based on amino acid sequence homology: the highly divergent N-terminal domain and the more conserved C-terminal domain ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Despite its variability across evolution, the N-terminus contains several highly conserved residues in mammalian species including three serine residues (S45, S47, S52 in *Homo sapiens* PPP1R35) previously found phosphorylated in large scale phospho-proteomic studies in both human and mouse cells ([@bib73]; [@bib19]; [@bib13]) ([Figure 5a](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In particular, S47 and S52 have been reported to be Cdk phosphorylation sites ([@bib13]) ([Figure 5a](#fig5){ref-type="fig"}). As such, we hypothesized that these residues could be candidates for regulating PPP1R35 activity during centrosome duplication, as Cdk2 ensures that centrosome duplication takes place concomitantly with DNA synthesis in S-phase ([@bib31]).

To probe the importance of these residues in the interaction with RTTN, we mutated all three serine residues to either non-phosphorylatable alanines (S45A, S47A, S52A) or to phospho-mimetic aspartic acids (S45D, S47D, S52D) and generated inducible HEK293 T-Rex Flp-In cell lines expressing the mutant N-terminal BirA\*-PPP1R35 constructs. Neither the triple alanine nor the triple aspartic acid mutant significantly impacted the presence of PPP1R35 at the centrosome, nor its proximity to RTTN ([Figure 5b,g](#fig5){ref-type="fig"}). Furthermore, co-IP demonstrated that neither phospho-mutant impacted the interaction between PPP1R35 and RTTN ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}).

We further evaluated the role of PPP1R35 phosphorylation on centriole duplication by examining whether the above phospho-mutants are able to rescue our centriole defect phenotype. When cells were depleted of endogenous PPP1R35 by the 3' UTR-targeting siRNA and expressed the triple aspartic acid mutant (S45D, S47D, S52D) GFP-PPP1R35 in trans, we did not observe any reduction in centrosome number ([Figure 5c](#fig5){ref-type="fig"}). Despite multiple attempts, we were unable to generate a triple alanine (S45A, S47A, S52A) mutant cell line in U2OS cells, therefore we examined both triple mutant cell lines in HEK293 cells ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). Analysis of individual alanine mutants (S45A and S47A) in U2OS cells is also consistent with the notion that that despite their conservation, these resides are not playing a critical for PPP1R35's function in centriole biogenesis ([Figure 5c](#fig5){ref-type="fig"}).

PPP1R35 is predicted to contain a canonical RVxF PP1-binding site ([@bib76]), encompassing residues 77--81 ([@bib46]) in the N-terminal domain. This site is conserved only among *Chordata* species ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Interestingly, disruption of the predicted PP1 binding site by mutating two conserved residues, V79 and F81, to alanine ([@bib76]) leads to proper targeting to the centriole ([Figure 5g](#fig5){ref-type="fig"}) and does not disrupt PPP1R35's proximity to, or interaction with, RTTN ([Figure 5d](#fig5){ref-type="fig"}, [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Furthermore, the V79A, F81A mutant nearly completely rescued our centriole duplication phenotype ([Figure 5e](#fig5){ref-type="fig"}), suggesting that it is not critical for centriole biogenesis.

PPP1R35 loss results in shortened centrioles by preventing the recruitment of proteins responsible for centriole elongation {#s2-7}
---------------------------------------------------------------------------------------------------------------------------

Since PPP1R35 forms a complex with the microcephaly protein RTTN and this protein has been previously linked to centriole elongation, where its loss resulted in shortened centrioles ([@bib12]), we investigated whether PPP1R35 knockdown results in diminished centriole length. To this effect, we used 3DSIM to measure the distance between the proximal end of centrioles labeled with acetylated tubulin to CP110, which localizes to the centriole's distal end ([Figure 6a](#fig6){ref-type="fig"}). Acetylated tubulin has been suggested to be an early tubulin modification during centriole duplication ([@bib4]) and it has been previously used for conducting centriole length measurements ([@bib12]). Furthermore, we verified that tubulin acetylation is unaffected when PPP1R35 is knocked down by siRNA ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To ensure that we were examining mature centrioles, we focused our analysis only on mother centrioles in G2 phase cells in which a clear mother and daughter centriole were present. The length of mother centrioles was determined to be 356 ± 65 nm in control-RNAi treated cells, in agreement with previous reports ([@bib93]). When PPP1R35 levels are knocked down by siRNA, we see a significant reduction in centriole length to 263 ± 69 and 246 ± 83 nm for the exon and 3' UTR siRNA, respectively ([Figure 6b](#fig6){ref-type="fig"}). On the contrary, overexpression of PPP1R35 does not significantly change centriole length (382 ± 89 nm). Due to the small effect observed on RTTN recruitment when PPP1R35 levels are reduced, we hypothesized that the shorter centriole length may be due to the inability of nascent centrioles to recruit proteins involved in elongation. We then examined cells treated with PPP1R35 siRNA for recruitment of proteins involved in either microtubule stabilization/recruitment such as CPAP and SPICE ([@bib1]; [@bib98]; [@bib91]; [@bib15]; [@bib62]) or the elongation of the distal portion of the centriole such as POC5 ([@bib3]) and both proteins were significantly reduced in the absence of PPP1R35. Consistently, CP110, a negative regulator of centriole elongation recruited early in the elongation pathway, was not significantly changed relative to control RNAi-treated cells ([Figure 6c](#fig6){ref-type="fig"}). Altogether, this demonstrates that PPP1R35 is a critical factor for centriole assembly by promoting recruitment of centriole elongation proteins.

![PPP1R35 loss results in short centrioles and impacts recruitment of positive-growth centriolar elongation factors.\
(**a**) Micrographs of representative centrosomes in U2OS cells stained with CP110 (green) and acetylated tubulin (red) with corresponding cartoon representation. By measuring the distances between the fluorescence maxima of CP110 and the proximal end of the acetylated tubulin signals (designated on the top micrograph by the grey lines) on the same z-plane using 3DSIM, the length of the centrioles was measured. (**b**) The lengths of centrioles from U2OS cells expressing GFP-PPP1R35 (n = 17) or treated with either control, scrambled siRNA (n = 14) or siRNA targeting an exon (n = 16) or 3'UTR of PPP1R35 (n = 17) for 72 hr plotted as a Tukey box and whisker plot. The average distances and standard deviations are noted in the plot. Statistical significance was determined by a two-tailed T-test. (**c**) To investigate the centriole elongation phenotype, U2OS cells were depleted of PPP1R35 by siRNA targeting an exon (red bars) or 3'UTR (orange bars) of PPP1R35 (grey bars, control siRNA) and subsequently stained for various proteins involved in centriole elongation. Statistics for significance were determined using Barnard's test. Statistical values can be found in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. (**d**) Our data demonstrate that PPP1R35 is involved in the CPAP-CEP120-SPICE pathway of centriole elongation and does not impact the CP110-CEP97 pathway, which restricts centriole elongation. (**e**) Proposed model of PPP1R35 function and mechanism in centriole biogenesis. In this study, we localized PPP1R35 to the proximal lumen of the centriole. By depleting cells of PPP1R35 via siRNA, we identify the step of its recruitment during centriole biogenesis to after cartwheel formation together with the microcephaly protein RTTN. Loss of PPP1R35 results in diminished CPAP, SPICE, POC1B and CEP295 with concomitant loss of downstream components including POC5 and CEP152. The loss of these components, implicated in centriole elongation, results in shortened centrioles.\
10.7554/eLife.37846.034Figure 6---source data 1.Source data for [Figure 6b](#fig6){ref-type="fig"} (centriole length measurements) and 6c (centriole elongation protein recruitment).](elife-37846-fig6){#fig6}

Discussion {#s3}
==========

PPP1R35 was initially suggested to be a centrosomal protein by mass spectrometry studies that identified PPP1R35 as co-purifying with isolated centrosomes ([@bib50]). Here we show that the uncharacterized protein PPP1R35 is stably associated at the centrosome throughout the cell cycle where it plays a critical role in its elongation. Our loss of function analysis places PPP1R35 relatively early in the centriole duplication pathway, after cartwheel formation and before complete centriole elongation. In addition, we demonstrate that the ultimate downstream effect of PPP1R35 loss is shortened centrioles, suggesting that PPP1R35 directly controls the elongation pathway. It is interesting to note that this diminished centriole duplication defect takes several days to become very pronounced suggesting that either the short centrioles are still competent to duplicate but to a diminished degree, or that only low levels of PPP1R35 are needed for proper biological activity. Phenotypic analysis places PPP1R35 upstream of CPAP, CEP295, SPICE and POC5, which are all proteins involved in centriole elongation ([@bib91]; [@bib62]; [@bib15]; [@bib10]), but downstream of RTTN, which also affects the recruitment of POC1B, POC5, and CEP295 similarly to PPP1R35 ([@bib12]). Furthermore, BioID, IP, and 3DSIM data show that PPP1R35 and RTTN form a protein complex and that this complex is likely a result of a direct interaction as RTTN is the only protein identified in both BioID and IP experiments.

Whereas several distal luminal proteins have been reported to date ([@bib3]; [@bib94]; [@bib74]), PPP1R35 is the first to be mapped to the proximal luminal region, an uncharacterized 'outpost' right above the cartwheel. Since most proteins involved in centriole elongation are localized along the microtubule wall or the distal end of the centriole ([@bib15]; [@bib44]; [@bib3]; [@bib82]), the interesting distribution of PPP1R35 suggests that it likely acts directly through RTTN, which our imaging show luminal localization for the N-terminus of the protein, in close proximity to PPP1R35.

Our phylogenetic analysis demonstrates that PPP1R35 is conserved in a wide range of species, including *Drosophila*, parasitic worms, and mammals ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). PPP1R35 is likely the human homolog of the *Drosophila* protein Reduction of Cnn dots 4 (Rcd4), a protein identified in a large RNAi screen aimed at discovering novel proteins impacting centrosome formation and PCM assembly ([@bib21]). Alignment of *Homo sapiens* PPP1R35 and *Drosophila* Rcd4 results in an overall similarity of 24%, with the greatest homology in the conserved C-terminal domain ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In all identified PPP1R35 homologs, the N-terminus exhibits a large degree of variability, hinting at an organism-specific specialization for this domain. We probed several conserved residues in PPP1R35 including several conserved serines (S45, S47, S52), but none of these mutants appeared to drastically impact centriole biogenesis. Intriguingly, the aforementioned serines and putative PP1-binding site, which are well conserved in *Chordata*, are not conserved in Rcd4. Furthermore, changes to the phosphorylation state did alter the overall BioID proximity map of PPP1R35, including altering the proximity to CEP85, AZI1, and OFD1, the latter two shown to have important roles in ciliogenesis ([@bib41]; [@bib64]; [@bib97]; [@bib80]; [@bib27]).

The centrosomal duplication cycle is closely linked to the cell cycle and tightly controlled by a host of kinases and phosphatases ([@bib77]; [@bib33]). While kinases inherently possess temporal and spatial specificity, protein phosphatases require a regulatory component to properly function ([@bib47]; [@bib76]; [@bib57]). To date, only a handful of centrosomal PP1 regulatory components have been identified ([@bib52]; [@bib67]; [@bib68]; [@bib45]; [@bib20]; [@bib49]) and overall knowledge of their interaction and role with PP1 is limited in scope. PPP1R35 is annotated to be a PP1-regulatory protein and contains a canonical PP1-binding site. Despite previous reports that demonstrated PP1-binding and inhibition ([@bib46]; [@bib26]), we were unable to identify any PP1 isoform in our BioID or IP screens using HEK293 cycling cells. This is not completely surprising as previous studies have encountered similar difficulties in identifying interactions between protein phosphatases and their interactors, frequently due to the transient nature of binding ([@bib88]). We tested the role of this interaction in regard to centriole duplication by mutating the canonical PP1-binding site but found that this interaction with PP1 does not appear to be critical for PPP1R35's role at the centrosome. Overall, this suggests that despite PPP1R35's annotation and previous demonstration as a PP1 regulator, this activity may not be related to centriole biogenesis. However, we cannot yet rule out the possibility that a second, non-canonical PP1-binding site is involved or that the PP1-regulating activity of PPP1R35 is required only in specific cellular functions not investigated here, such as ciliogenesis. Nonetheless, the large number of robust, non-centrosomal BioID hits suggests that PPP1R35 may serve other functions in the cell apart from centriole duplication and perhaps these other functions require PPP1R35's PP1-regulation activity.

Despite the importance of centriole elongation to numerous human diseases, the exact mechanisms through which elongation takes place is still poorly understood ([@bib63]). To date, two major pathways governing centriole elongation have been described, one positive-growth mechanism acting on assisting microtubule elongation (CPAP/CEP120/SPICE) ([@bib56]; [@bib82]; [@bib91]; [@bib62]; [@bib15]) and a second negative-growth mechanism involving CP110 and CEP97, which form a cap-like structure on the centriole to restrict microtubule growth ([@bib82]; [@bib87]; [@bib30]; [@bib11]). However, even with the discovery of additional proteins such as POC5 ([@bib3]), CEP295 ([@bib10]), and Centrobin ([@bib38]), all of which impact centriole elongation, we apparently have yet to acquire a complete picture of this process. Here, we have identified a novel key player of this process, PPP1R35. Our data suggest that PPP1R35 primarily impacts the CPAP/CEP120/SPICE and RTTN/CEP295 pathways of centriole elongation ([Figure 6d,e](#fig6){ref-type="fig"}). Previously, RTTN was proposed to be critical for stabilizing the early procentriole containing STIL, CPAP, and SAS6 and for recruiting CEP295, which in turn can recruit POC5 and POC1B ([@bib12]). Our data are consistent with a model where the impact on centriole elongation occurs primarily through PPP1R35's interaction with RTTN. Such a role is consistent with the localization of both PPP1R35 and RTTN, which are uniquely positioned just above the cartwheel in the region where elongation following initial centriole formation would occur. PPP1R35 could be involved in either modulating RTTN's turnover or interactions with other proteins. This reasoning is supported by the observation that RTTN loss has been shown to cause lack of proper CEP295, POC1B, and POC5 recruitment and an interdependency with CPAP and CEP135 ([@bib12]), consistent with our observed phenotype when PPP1R35 is knocked down.

Mutations in numerous centriolar proteins have been linked to microcephaly ([@bib5]; [@bib51]), including components involved in centriole elongation such as CPAP ([@bib58]) and RTTN ([@bib8]; [@bib35]). The discovery of additional microcephaly proteins will aid in our understanding of the disease and assist in the development of future therapies. Our data show that that PPP1R35 impacts the process of centriole elongation through a close relationship with a known microcephaly protein, RTTN, therefore suggesting that PPP1R35 may be one such candidate microcephaly gene. Future DNA sequencing of microcephaly patients and animal model studies are needed to address this issue.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\            Designation                   Source or reference          Identifiers                                                                         Additional\
  (species) or resource                                                                                                                                                   information
  ------------------------ ----------------------------- ---------------------------- ----------------------------------------------------------------------------------- -----------------------
  Gene (human)             PPP1R35                       MGC clone,\                  4773899                                                                             
                                                         TCAG (SickKids)                                                                                                  

  Gene (human)             RTTN                          GE Dharmacon\                25914                                                                               
                                                         ORFeome                                                                                                          

  Cell line (human)        U2OS                          ATCC                         HTB-96,\                                                                            
                                                                                      RRID: [CVCL_0042](https://scicrunch.org/resolver/CVCL_0042)                         

  Cell line (human)        HEK293 TREX Flp-In            Thermo Fisher\               R78007,\                                                                            
                                                         Scientific                   RRID: [CVCL_U427](https://scicrunch.org/resolver/CVCL_U427)                         

  Cell line (human)        U2OS Flp-In                   Trimble Lab/SickKids                                                                                             Generous gift from\
                                                                                                                                                                          Trimble Lab

  Antibody                 GFP                           Abcam                        ab13970,\                                                                           1:2000 (IF)
                                                                                      RRID: [AB_300798](https://scicrunch.org/resolver/AB_300798)                         

  Antibody                 mCherry                       Life Technologies            M11217,\                                                                            1:200 (IF)
                                                                                      RRID: [AB_2536611](https://scicrunch.org/resolver/AB_2536611)                       

  Antibody                 CETN1                         Millipore                    04--1624,\                                                                          1:200 (IF)
                                                                                      RRID: [AB_10563501](https://scicrunch.org/resolver/AB_10563501)                     

  Antibody                 CEP152                        Bethyl                       A302-480A,\                                                                         1:500 (IF)
                                                                                      RRID: [AB_1966084](https://scicrunch.org/resolver/AB_1966084)                       

  Antibody                 CEP135                        Bethyl                       A302-250A,\                                                                         1:500 (IF)
                                                                                      RRID: [AB_1730796](https://scicrunch.org/resolver/AB_1730796)                       

  Antibody                 CPAP                          ProteinTech                  11517--1-AP,\                                                                       1:50 (IF)
                                                                                      RRID: [AB_2244605](https://scicrunch.org/resolver/AB_2244605)                       

  Antibody                 SAS6                          Santa Cruz                   sc-81431,\                                                                          1:200 (IF)
                                                                                      RRID: [AB_1128357](https://scicrunch.org/resolver/AB_1128357)                       

  Antibody                 POC5                          Bethyl                       A303-341A,\                                                                         1:500 (IF)
                                                                                      RRID: [AB_10971172](https://scicrunch.org/resolver/AB_10971172)                     

  Antibody                 POC1B                         Invitrogen                   PA5-24495,\                                                                         1:50 (IF)
                                                                                      RRID: [AB_2541995](https://scicrunch.org/resolver/AB_2541995)                       

  Antibody                 Gamma-Tubulin                 Sigma                        T6557, RRID: [AB_477584](https://scicrunch.org/resolver/AB_477584)                  1:5000 (IF)

  Antibody                 CEP250                        ProteinTech                  14498--1-AP,\                                                                       1:50 (IF)
                                                                                      RRID: [AB_2076918](https://scicrunch.org/resolver/AB_2076918)                       

  Antibody                 CEP295                        Abcam                        ab122490,\                                                                          1:100 (IF)
                                                                                      RRID: [AB_11129892](https://scicrunch.org/resolver/AB_11129892)                     

  Antibody                 RTTN                          Abcam                        ab113541                                                                            1:50 (IF)

  Antibody                 Polyglutamylated\             AdipoGen                     AG-20B-0020-C100                                                                    1:400 (IF)
                           tubulin                                                                                                                                        

  Antibody                 CP110                         ProteinTech                  12780--1-AP,\                                                                       1:200 (IF)
                                                                                      RRID: [AB_10638480](https://scicrunch.org/resolver/AB_10638480)                     

  Antibody                 SPICE                         Atlas                        HPA064843,\                                                                         1:500 (IF)
                                                                                      RRID: [AB_2685367](https://scicrunch.org/resolver/AB_2685367)                       

  Antibody                 GAPDH                         Abcam                        ab181602,\                                                                          1:500 (IF); 1:1000\
                                                                                      RRID: [AB_2630358](https://scicrunch.org/resolver/AB_2630358)                       (Western Blot)

  Antibody                 GAPDH                         Millipore                    MAB374,\                                                                            1:200 (IF)
                                                                                      RRID: [AB_2107445](https://scicrunch.org/resolver/AB_2107445)                       

  Antibody                 GFP (for Westerns)            Life\                        A11122,\                                                                            1:2000 (Western Blot)
                                                         Technologies                 RRID: [AB_221569](https://scicrunch.org/resolver/AB_221569)                         

  Antibody                 FLAG-tag                      Sigma                        F3165-1MG                                                                           1:500 (IF)

  Antibody                 Anti-rabbit HRP\              Cell Signalling              7074S,\                                                                             1:2000 (Western Blot)
                           (for Westerns)                                             RRID: [AB_2099233](https://scicrunch.org/resolver/AB_2099233)                       

  Antibody                 PPP1R35                       ProteinTech                  24214--1-AP                                                                         1:50 (IF)

  Antibody                 Acetylated tubulin            Sigma                        T7451, RRID: [AB_609894](https://scicrunch.org/resolver/AB_609894)                  1:400 (IF)

  Antibody                 γ-tubulin                     Sigma                        T6557, RRID: [AB_477584](https://scicrunch.org/resolver/AB_477584)                  1:5000 (IF)

  Recombinant\             pIRES Centrin\                Addgene                      64338                                                                               Deposited by\
  DNA reagent              1 mCherry                                                                                                                                      Matthieu Piel

  Recombinant\             pcDNA5-FRT-\                  DOI: 10.1083/jcb.201106131                                                                                       Created by\
  DNA reagent              To-Sept2p                                                                                                                                      Moshe Kim

  Recombinant\             pcDNA5/FLAG/\                 10.1074/mcp.M114.045658                                                                                          Created by the\
  DNA reagent              TO-FLAG-BirA\*                                                                                                                                 Raught Lab

  Recombinant\             pcDNA5/FLAG/\                 10.1074/mcp.M114.045658                                                                                          Created by the\
  DNA reagent              TO-BirA\*-FLAG                                                                                                                                 Raught Lab

  Recombinant\             pOG44                         Thermo Fisher\               V600520                                                                             
  DNA reagent                                            Scientific                                                                                                       

  Sequence-based\          Scrambled siRNA               Ambion\                      4390844                                                                             
  reagent                                                (Life Technologies)                                                                                              

  Sequence-\               GAPDH siRNA                   Ambion\                      4390850                                                                             
  based reagent                                          (Life Technologies)                                                                                              

  Sequence-based\          PPP1R35,\                     Ambion\                      s48124                                                                              
  reagent                  exon siRNA                    (Life Technologies)                                                                                              

  Sequence-based\          PPP1R35, 3\'\                 Ambion\                      s195859                                                                             
  reagent                  UTR siRNA                     (Life Technologies)                                                                                              

  Sequence-based reagent   RTTN siRNA                    Ambion\                      RTTNHSS119506                                                                       
                                                         (Life Technologies)                                                                                              

  Commercial\              PureLink PCR\                 Thermo Fisher\               K310001                                                                             
  assay or kit             Purification Kit              Scientific                                                                                                       

  Commercial\              DNA Gel\                      Qiagen                       28704                                                                               
  assay or kit             Extraction Kit                                                                                                                                 

  Commercial\              Gibson\                       New England\                 E2611S                                                                              
  assay or kit             Assembly Kit0                 Biolabs                                                                                                          

  Commercial\              QuikChange II\                Agilent                      200523                                                                              
  assay or kit             XL Lightning\                                                                                                                                  
                           Mutagenesis Kit                                                                                                                                

  Commercial\              Mycoplasma\                   Invitrogen                   M7006                                                                               
  assay or kit             Detection Kit                                                                                                                                  

  Commercial\              JetPrime\                     Polyplus                     114--07                                                                             
  assay or kit             Transfection Reagent                                                                                                                           

  Commercial\              Lipofectamine\                Invitrogen                   13778150                                                                            
  assay or kit             RNAiMax                                                                                                                                        

  Commercial\              GeneJet RNA\                  Thermo Fisher\               K0731                                                                               
  assay or kit             Purification Kit              Scientific                                                                                                       

  Commercial\              RapidOut DNA\                 Thermo Fisher\               K2981                                                                               
  assay or kit             Removal Kit\                  Scientific                                                                                                       

  Commercial\              iScript cDNA\                 BioRad                       1708890                                                                             
  assay or kit             Synthesis Kit                                                                                                                                  

  Commercial\              SsoAdvanced Universal\        BioRad                       1725271                                                                             
  assay or kit             SYBR Green Supermix                                                                                                                            

  Software,\               Barnard\'s Test (R Package)   Kamil Erguler                [[https://github.com/kerguler/Barnard]{.ul}](https://github.com/kerguler/Barnard)   
  algorithm                                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmids and molecular biology {#s4-1}
------------------------------

Tables detailing primers ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) and siRNA strands ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) used in this study are available in the Supplemental Material section. The construct pIRES Centrin1 mCherry was a gift from Matthieu Piel (Addgene plasmid \# 64338). For cloning experiments, PCR products were amplified from plasmid cDNA (PPP1R35 cDNA, MGC clone Image ID 4773899; RTTN cDNA, GE Dharmacon ORFeome cDNA 25914), verified for specificity of amplification on an agarose gel and purified using the PureLink PCR Purification kit (Thermo Fisher Scientific) or gel-extracted (Qiagen DNA Gel Extraction Kit) when necessary. All cloning experiments were conducted using Gibson Assembly (New England Biolabs) according to the manufacturer's instructions. Site-directed mutagenesis for the single serine mutants was conducted using QuikChangeII XL Lightning site-directed mutagenesis kit (Agilent). Gene synthesis (Invitrogen GeneArt) was used to generate mutant PPP1R35 containing the triple Ala, Asp, and V79A, F81A mutations and were subsequently cloned into the GFP-containing FRT vector via Gibson Assembly as described above. Newly generated plasmid constructs were verified using Sanger Sequencing (ACGT Corp., Toronto).

Cell culture {#s4-2}
------------

U2OS and U2OS Flp-In cells were cultured in McCoy's 5A medium (Gibco) supplemented with 10% fetal bovine serum (Wisent) and 1 X antibiotic/antimycotic (Gibco, 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B). HEK 293T TREX cells were maintained in Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% tetracycline-free fetal bovine serum (Wisent) and 1 X antibiotic/antimycotic. All cells were cultured at 37°C with 5% CO~2~ and routinely passed. The cells were tested routinely for mycoplasma contamination using Invitrogen's Mycoplasm Detection Kit.

For cellular transfection of DNA plasmids, JetPrime (Polyplus) was used according to the manufacturer's instructions. Cells were subsequently selected in the appropriate antibiotic (puromycin for constructs in U2OS Flp-In cells and hygromycin for constructs in HEK293 Flp-In TREX cells) to generate cell lines with stably integrated transgenes. For siRNA transfections, Lipofectamine RNAiMax (Invitrogen) was used according to the manufacturer's instructions. All siRNA strands were transfected at a final concentration of 40 nM and cells were assayed 72 hr post transfection. Scrambled siRNA and siRNA targeting GAPDH were used as negative and positive controls, respectively. GAPDH control knockdown efficacy was monitored by immunofluorescence and by western blot. The number of labeled centrosomes per cell (classified into categories as either 0, 1, 2 or \>2 labeled centrosome; see [Figure 3d](#fig3){ref-type="fig"} for example of centrosome spots imaged in cells and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"} for example of categories of centrosomal counts) were manually counted and all siRNA experiments were conducted in at least triplicate except for the HEK293 siRNA experiments that were conducted in at least duplicate.

Live-cell imaging {#s4-3}
-----------------

For live-cell imaging, cells were seeded on KOH-washed coverglass (Electron Microscope Sciences) to reduce background fluorescence and subsequently left overnight to adhere. The standard culture media was replaced with DMEM medium lacking phenol red (Gibco) supplemented with 10% fetal bovine serum and 1 X antibiotic/antimycotic. Cells were imaged on a Zeiss Axio Observer Spinning-disc microscope equipped with Yogokawa spinning disk head, Phototronics EM CCD camera, and a 63x objective (NA = 1.4). The samples were maintained at 37°C with 5% CO~2~ during imaging in an incubation chamber. Automated acquisition of a 30 µm z-stack with a 0.75 µm step size every 40--45 min was obtained using the Zeiss Zen Blue software. During acquisition the lowest possible minimal laser power was used to avoid phototoxicity, resulting in movies of an average length of 14 hr.

Fluorescence recovery after photobleaching (FRAP) experiments {#s4-4}
-------------------------------------------------------------

The cells were imaged on a Leica SP8 Confocal DMI6000 microscope equipped with a HyD detector and a 63x (NA = 1.4) oil objective. The samples were maintained at 37°C with 5% CO~2~ during imaging in an incubation chamber. Samples were bleached with a white light laser for approximately 1.5 s and the subsequent recovery monitored for an additional 26.5 s. The resultant plots were analyzed and fit to a single exponential curve using the build-in FRAP analysis function in the Leica Analysis Suite X software.

Immunofluorescence {#s4-5}
------------------

A table detailing all antibodies used in this study, including concentrations and suppliers, is available in the key resources table. Cells were plated onto coverslips (Electron Microscope Sciences; previously cleaned with KOH) and left overnight to adhere. The cells were treated with 0.02% w/v digitonin in PBS for 5 min at RT to remove the cytoplasmic population of PPP1R35 followed by fixation with −20°C methanol for 20 min. The cells were blocked for 1 hr using 5% FBS in PBS supplemented with 0.5% Tween-20. The cells were incubated with primary and secondary antibodies for 40 min each at RT. To detect specific primary antibodies, Alexa 488-, Alexa 568-, or Alexa 647-conjugated IgGs were used as secondary antibodies at a dilution of 1:1000 (Invitrogen). Cell nuclei were stained with Hoescht 33342 (Thermo Fisher). Cells were mounted with 0.5% n-propyl gallate in 80% glycerol mounting media.

3D structured illumination microscopy {#s4-6}
-------------------------------------

3DSIM data were collected using an ELYRA PS.1 (Carl Zeiss Microscopy) with a Plan-Apochromat 63x or 100x/1.4 Oil immersion objective lens with an additional 1.6x optovar. An Andor iXon 885 EMCCD camera was used to acquire images with 101 nm/slice z-stack intervals over a 5--10 µm thickness. The fluorophores were excited with 405, 488, 555 and 647 nm wavelengths and band-pass 420--480, 495--550, 570--620, long-pass 655 and 750 nm filters were used to collect the emission wavelengths. Laser powers at the objective focal plane of 52.6 mW in the 2--12% range, exposure time between 50--250 ms and EMCCD camera gain values between 5 and 50 were used during image acquisition. For each image field, grid excitation patterns were collected for five phases and three rotation angles (−75^o^; −15^o^, +45^o^). The raw data were reconstructed using the SIM module of ZEN Black Software (version 8.1) with noise filter values between −6 and −3. Channel alignment was conducted using calibrated file generated from super-resolution Tetraspec beads (Carl Zeiss Microscopy). If appropriate, whole-volume images or maximum intensity projections were exported as tiff files to be further analyzed in ImageJ/Fiji (NIH).

Protein mapping and centriole length measurements by 3DSIM {#s4-7}
----------------------------------------------------------

To measure the position of PPP1R35 relative to various centriolar markers, only 3DSIM images in which both the fluorescence maxima of PPP1R35 and the corresponding reference protein were on the same z-slice were analyzed. The distance between the peak maxima for the two markers were determined using the caliper function built in to the Zeiss Zen Black software (see [Figure 2c](#fig2){ref-type="fig"} for an example). The centriole length measurements were conducted in an identical manner using CP110 as a distal end marker and the acetylated tubulin signal as a proximal end marker (see [Figure 6a](#fig6){ref-type="fig"} for an example).

Proximity-dependent biotinylation {#s4-8}
---------------------------------

BioID was conducted as previously described ([@bib28]; [@bib40]). To generate stable cell lines expressing recombinant BirA fusion proteins for BioID experiments, HEK293 Flp-In T-Rex cells were co-transfected with the pcDNA5/FRT/TO PPP1R35-FLAG-BirA\* or pcDNA5/FRT/TO FLAG-BirA\*-PPP1R35 plasmid and Flp Recombinase Expression plasmid pOG44 in a 1:20 ratio, and then selected for multiple passages with increasing antibiotics concentrations to reach final concentrations of 400 µg/ml Hygromycin B (Invitrogen) and 15 µg/ml Blasticidin (Gibco, Thermo Fisher Scientific). HEK293 TREX Flp-In cells expressing the appropriate transgene were cultured until 90--100% confluency and treated for 24 hr with 1 µg/ml tetracycline to induce BirA expression and 50 µM biotin to allow biotinylation of proteins. HEK293T TREX Flp-In cells transfected with a vector containing either the N- or C-terminal FLAG-BirA\* but no PPP1R35, were processed in parallel as controls.

Cells were collected, pelleted, and washed three times with PBS prior to freezing. Cell pellets were processed for Bio-ID and FLAG ImmunoPrecipitation (IP) experiments as described previously ([@bib17]). Interactor classification: bona fide interactors were defined as high confidence protein identifications (ProteinProphet p\>0.85) with a SAINT score ≥0.75, based on 4 independent MS runs. Histone hits were eliminated. Fold-change was calculated as described previously ([@bib17]).

Western blot {#s4-9}
------------

Total cell lysates were collected using RIPA lysis buffer (Pierce) supplemented with mammalian protease inhibitor (BioBasic; 100 mM PMSF, 1 mM Bestatin, 1.5 mM Pepstatin A, 1.4 mM E-64, 0.08 mM Aprotinin, 1 mM Leupeptin) and cell debris pelleted by spinning for 30 min at 12,000 rpm. Protein concentrations were determined using a BCA protein assay kit (Pierce). Protein lysate containing \~15--30 µg of total protein was loaded onto well of 4--12% Bis-Tris gels (Invitrogen). Proteins were transferred to nitrocellulose membrane for 2 hr on an Invitrogen Bolt Minigel Apparatus at 10 V and blocked with 5% skim milk for 1 hr. Membranes were subsequently incubated with specific antibodies overnight at 4°C. Secondaries conjugated with HRP (Cell Signalling) were used at a 1:2000 dilution. Blots were developed using the ECL Chemiluminescent Substrate Kit (Invitrogen).

Real-time quantitative polymerase chain reaction (RT-qPCR) {#s4-10}
----------------------------------------------------------

RNA was extracted from cells using the GeneJet RNA Purification kit (Thermo Scientific) and subsequently treated with the RapidOut DNA Removal kit (Thermo Scientific). Purified RNA was quantitated and only RNA with an A260/A280 ratio greater than 1.8 was used for reverse transcription with the BioRad iScript cDNA Synthesis kit with 1 µg of RNA as the template. All quantitative PCR was performed using a CFX Connect Real-Time System (BioRad) with SsoAdvanced Universal SYBR Green Supermix (BioRad) and 500 nM combined primer concentration per well. The relative expression of the target genes were normalized to RNA polymerase II and TATA binding protein transcript levels for each condition and then relative to expression in the scrambled siRNA-treated sample. Primer sequences can be found in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. No-template and no-reverse transcriptase controls were run for each primer pair to confirm the lack of primer--dimer formation/DNA contamination and genomic DNA contamination, respectively. At least three biological replicates were run per condition. Data were analyzed using the CFX Maestro software (BioRad). All kits were conducted as per the manufacturer's protocol.

Statistical analysis {#s4-11}
--------------------

All siRNA experiments were analyzed as 2 × 2 contingency tables in which all cells for a given population (i.e. cells with \>1 CEP152 spots) were pooled for all replicates. To determine the p-values compared to the scrambled siRNA control for each dataset, Barnard's Test was used in R with unpooled variances (package by Kamil Erguler; available at <https://github.com/kerguler/Barnard>) ([@bib24]). A summary of all statistics for the siRNA experiments can be found in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. For all other statistical tests, the Student's T-Test was used. Error bars represent the standard deviation for all replicates. For all figures, the following conventions were used: ns (p\>0.05), \* (p≤0.05), \*\* (p≤0.01), \*\*\* (p≤0.001), \*\*\*\* (p≤0.0001).

Phylogenetics {#s4-12}
-------------

The NCBI protein database was queried with the search term 'PPP1R35' and all resultant hits were downloaded. For species with multiple annotated isoforms, the longest was selected. Any entries that were also annotated as a protein of known function (i.e. transposase, helicase, etc) were removed. Furthermore, only one organism per genus was selected to ensure broad coverage yet avoiding artifacts caused by over-sampled genera. All entries were from the *Holozoa* group of Eukaryotes. In order to ensure that no sequences from other major eukaryotic groups were missed, Delta Blastp searches using both the *Homo sapien* and *Drosophila melanogaster* PPP1R35 sequences were used to search for homologs in representative genera from the remaining eukaryotic groups (exact genera probed are those found in [Figure 1](#fig1){ref-type="fig"} of Ref. \[[@bib48]\]). No additional homologs were identified outside of the *Holozoa*. Multiple sequence alignments were performed using Clustal Omega ([@bib84]) with the default settings. The phylogeny was inferred using the Bayesian method implemented with MrBayes v. 3.2.6 (mixed amino acid rate mode) and run for 2.5 million generations until the standard deviation of split frequencies was 0.199. *Drosophila melanogaster* Sds22, a PP1 regulator protein identified to have diverged early from homologous PP1 regulators ([@bib9]), was used as the outgroup. Trees were drawn using FigTree v. 1.4.3.
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###### Raw BioID and Immunoprecipitation Data.

Compilation of all BioID and immunoprecipitation data for all BirA\*-tagged constructs used in this study.
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###### Primers used in this study.

Unless otherwise noted, all primers were used as a part of a Gibson Assembly based cloning strategy.
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###### Sequences and manufacture's ID for siRNAs used in this study.

All siRNAs were from Ambion (by Life Technologies) except for RTTN that was from Thermo/Invitrogen. Upper case letters represent bases that are present in the target's mRNA sequence.
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###### Summary of all statistics used in this study. 

Corresponding figure numbers are indicated. All statistics in this table were conducted using Barnard\'s Exact Test, unless otherwise noted.
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Data availability {#s7}
-----------------

All data generated or analyzed during this study are included in the manuscript and supporting files.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"PPP1R35 is a Novel Centrosomal Protein that Regulates Centriole Length In Concert with the Microcephaly Protein RTTN\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Yukiko M Yamashita as the Reviewing Editor and Reviewer \#1 and the evaluation has been overseen by Anna Akhmanova as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors identified PPP1R35 as a novel regulator for centriole formation. They demonstrated that PPP1R35 is a resident centriole protein using live-cell imaging. Using 3DSIM, the authors localize PPP1R35 to an under-characterized portion of the centriole: the inner lumen, immediately distal to the cartwheel. Functional analysis with specific siRNAs against the ORF and 3\' UTR revealed that PPP1R35 reduction of function led to a moderate decrease in the number of CEP152 spots and consistently defects in recruitment of components for centriole elongation such as CEP295, SPICE, CPAP and RTTN. Furthermore, BioID and co-IP experiments provided evidence for interactions of PPP1R35 with known centrosomal proteins especially with a significant hit of RTTN, a recently-characterized protein for centriole elongation. Indeed, their localization at centrioles is mutually dependent each other with RTTN having a more significant impact for the PPP1R35 centriolar localization, suggesting that RTTN may be upstream of PPP1R35. Overall, this work will significantly impact the field through the characterization of a novel centriole protein which exists in the centriolar lumen and is essential for centriole growth, two poorly understood aspects of centriole biology. Additionally, this work further details and maps the proteins within distinct regions of the centriole along the proximal-distal axis.

We would like to ask the following issues to be addressed in revision.

Essential revisions:

1\) The reviewers are concerned that PPP1R35\'s localization is assessed only by overexpression of a GFP tagged version, leaving the possibility that this localization might not reflect endogenous one. To address this issue, the authors should (1) use antibody (if a validated one is readily (e.g. commercially) available, but we do not ask to try all possible commercially available ones); (2) if the localization study of the endogenous protein cannot be examined, then the authors should characterize centriole morphology etc. whether or not the overexpression of GFP construct does not interfere centriole/centrosome biogenesis.

2\) The efficiency of siRNA knockdown is somewhat unclear (Figure 3---figure supplement 1 only shows siRNA efficiency using cells expressing GFP-tagged protein). We don\'t know the endogenous level, and how it compares to the expression level of GFP-tagged version. And accordingly, we don\'t know how much endogenous protein is depleted upon siRNA. Thus, we would like to see a bit more of validation of the phenotype and/or siRNA efficiency. One can try RT-qPCR to see the knockdown efficiency (using wild type cells + siRNA).

10.7554/eLife.37846.042

Author response

> Essential revisions:
>
> 1\) The reviewers are concerned that PPP1R35\'s localization is assessed only by overexpression of a GFP tagged version, leaving the possibility that this localization might not reflect endogenous one. To address this issue, the authors should (1) use antibody (if a validated one is readily (e.g. commercially) available, but we do not ask to try all possible commercially available ones); (2) if the localization study of the endogenous protein cannot be examined, then the authors should characterize centriole morphology etc. whether or not the overexpression of GFP construct does not interfere centriole/centrosome biogenesis.

We tested six commercially available antibodies in localization experiments. One antibody (ProteinTech 24214-1-AP) generated consistent results to demonstrate co-localization at the centrosome with centriolar markers despite high cytoplasmic and punctate background. To further validate that GFP-PPP1R35 localization reflects the endogenous one, we also examined centrosome morphology of WT and GFP-PPP1R35-expressing U2OS cells labeled with various centrosomal markers by 3DSIM microscopy (see Figure 1---figure supplement 1). In these experiments, we did not observe centriolar defects in the U2OS GFP-PPP1R35 expressing line. Furthermore, in the same line we did not observe defects in centrosome biogenesis relative to WT cells, when comparing the distribution of cells with 0, 1, 2 or \> 2 CEP152-labeled centrosomes, since nearly identical distributions of centrosome number were observed. These observations, taken together with the ability of the GFP-PPP1R35 construct to rescue PPP1R35 siRNA knock-down, strongly suggest that this construct is localizing similarly to the endogenous protein and does not impact centrosome structure or biogenesis.

To specifically address this point in the manuscript, we added new panels to Figure 1 (Figure 1D and E) and a new supplemental figure (Figure 1---figure supplement 1), which includes micrographs comparing WT and GFP-PPP1R35-expressing U2OS cells and a graph comparing the distribution of centrosome number in the two cell lines. Furthermore, we added the following to subsection "PPP1R35 is stably associated with the centrosome throughout the cell cycle":

"To confirm that GFP-PPP1R35 localization is consistent with the endogenous protein, we imaged U2OS cells, stained with antibodies against PPP1R35 and γ-tubulin, by confocal microscopy (Figure 1D) and cells labeled with antibodies against PPP1R35 and CETN1 by 3D structured illumination microscopy (3DSIM), and observed proximity or co-localization (Figure 1E). \[...\] In addition, the construct rescues the centriole duplication phenotype when PPP1R35 levels are knocked down by siRNA (see below; Figure 3C)."

> 2\) The efficiency of siRNA knockdown is somewhat unclear (Figure 3---figure supplement 1 only shows siRNA efficiency using cells expressing GFP-tagged protein). We don\'t know the endogenous level, and how it compares to the expression level of GFP-tagged version. And accordingly, we don\'t know how much endogenous protein is depleted upon siRNA. Thus, we would like to see a bit more of validation of the phenotype and/or siRNA efficiency. One can try RT-qPCR to see the knockdown efficiency (using wild type cells + siRNA).

To verify the efficiency of the RNAi knockdown, we conducted RT-qPCR experiments using two sets of primers specific for *c7orf47* (PPP1R35). Using both primer sets, we observed a pronounced knockdown of the endogenous mRNA. We updated the text subsection "PPP1R35 is critical for centriole component recruitment" to reflect this data, which is included as a new figure (Figure 3---figure supplement 1). The Materials and methods section was also updated with the corresponding experimental methodology and the sequences of the primers used are now included in Supplementary file 2.
